We are live on ! Find out more

iShares Biotechnology ETF

IBB

Market cap $11.4B

215.32 USD

-2.29

1.05%

At close Updated Nov 2, 12:48 PM EST

1 day

-1.05%

5 days

3.4%

1 month

4.89%

3 months

15.82%

6 months

26.54%

Year to date

27.41%

1 year

36.75%

5 years

32.37%

10 years

153.97%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 39.3%

Neutral 46.4%

Negative 14.3%

Zacks Investment Research

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Designed to provide broad exposure to the Health Care ETFs category of the market, the iShares Biotechnology ETF (IBB) is a smart beta exchange traded fund launched on 02/05/2001.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

24/7 Wall Street

$10,000 in Vanguard's Health Care ETF in 2004 Grew to $93,915, and It Still Charges 0.09%

A single health care ETF launched two decades ago at rock-bottom cost has quietly compounded into a sum that surprises most investors, but whether its three closest rivals can match it depends entirely on what kind of risk you are

$10,000 in Vanguard's Health Care ETF in 2004 Grew to $93,915, and It Still Charges 0.09%

24/7 Wall Street

Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFs

Regeneron (NASDAQ:REGN | REGN Price Prediction) shares rose 13.55% in Friday's session, trading at $929.69 as of 9:45 AM ET on Oct 30, 2026. For a biotech worth roughly $94.

Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFs

Zacks Investment Research

Should You Invest in the iShares Biotechnology ETF (IBB)?

Launched on February 5, 2001, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

Should You Invest in the iShares Biotechnology ETF (IBB)?

Zacks Investment Research

ETFs That You May Consider Amid a Strengthening Biotech Outlook

Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.

ETFs That You May Consider Amid a Strengthening Biotech Outlook

The Motley Fool

Invesco's RSPH or iShares' IBB: Which Healthcare ETF Is the Better Long-Term Buy?

Invesco S&P 500 Equal Weight Health Care ETF offers a lower expense ratio and a higher dividend yield than iShares Biotechnology ETF. iShares Biotechnology ETF provides concentrated biotech exposure while Invesco S&P 500 Equal Weight Health Care ETF covers the broader healthcare sector.

Invesco's RSPH or iShares' IBB: Which Healthcare ETF Is the Better Long-Term Buy?

Biotech stocks are surging. How investors can play the new drug innovation boom

Biotech stocks are rallying as clinical wins, M&A and new drug technologies revive the sector. Here are the ETFs and stocks analysts favor.

Biotech stocks are surging. How investors can play the new drug innovation boom

24/7 Wall Street

Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher

Healthcare is drawing fresh buying as money moves away from the market's popular technology trade, and one messenger RNA (mRNA) name is pulling well ahead of the pack. Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares are up 6% to $239.

Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher

The Motley Fool

Better Buy: Fidelity Health Care ETF (FHLC) or iShares Biotechnology ETF (IBB)?

Fidelity MSCI Health Care Index ETF offers a significantly lower expense ratio of 0.08% compared to 0.44% for the iShares Biotechnology ETF. iShares Biotechnology ETF is more concentrated, with 87% of its portfolio in biotechnology stocks.

Better Buy: Fidelity Health Care ETF (FHLC) or iShares Biotechnology ETF (IBB)?

From Laggard to Leader: The Surprising Comeback of Healthcare

Healthcare stocks have finally stepped back into the spotlight. After spending much of the past several years in the shadow of technology and AI, the sector has quietly emerged as one of the year's more compelling comeback stories.

From Laggard to Leader: The Surprising Comeback of Healthcare

See News Rankings

Price charts implemented using Lightweight Charts™